1. age \<18 years 2. unable to give informed consent 3. pregnant women or breast-feeding mothers 4. previous transfusion reaction or other contraindication to a plasma transfusion 5. known hypersensitivity to camostat mesylate and/or severe pancreatitis 6. volume stress due to cp administration would be intolerable 7. known iga deficiency 8. life expectancy \< 6 months 9. duration sars-cov-2 typical symptoms \> 3 days 10. sars-cov-2 pcr detection older than 3 days 11. sars-cov-2 associated clinical condition \>= who stage 3 (patients hospitalized for other reasons than covid-19 may be included if they fulfill all inclusion and none of the exclusion criteria). 12. previously or currently hospitalized due to sars-cov-2 13. previous antiviral therapy for sars-cov-2 14. alanine aminotransferase (alt) or aspartate transferase (ast) \> 5 times upper limit of normal (uln) at screening 15. liver cirrhosis \> child a (patients with child b/c cirrhosis are excluded from the trial) 16. chronic kidney disease with gfr \< 30 ml/min 17. concurrent or planned anticancer treatment during trial period 18. accommodation in an institution due to legal orders (§40(4) amg). 19. any psycho-social condition hampering compliance with the study protocol. 20. evidence of current drug or alcohol abuse. 21. use of other investigational treatment within 5 half-lives of enrollment is prohibited 22. previous use of convalescent plasma for covid-19 23. concomitant proven influenza a infection 24. patients with organ or bone marrow transplant in the three months prior to screening visit

1. age \<18 years 2. unable to give informed consent 3. pregnant women or breast-feeding mothers 4. previous transfusion reaction or other contraindication to a plasma transfusion 5. known hypersensitivity to camostat mesylate and/or severe pancreatitis 6. volume stress due to cp administration would be intolerable 7. known iga deficiency 8. life expectancy \< 6 months 9. duration sars-cov-2 typical symptoms \> 3 days 10. sars-cov-2 pcr detection older than 3 days 11. sars-cov-2 associated clinical condition \>= who stage 3 (patients hospitalized for other reasons than covid-19 may be included if they fulfill all inclusion and none of the exclusion criteria). 12. previously or currently hospitalized due to sars-cov-2 13. previous antiviral therapy for sars-cov-2 14. alanine aminotransferase (alt) or aspartate transferase (ast) \> 5 times upper limit of normal (uln) at screening 15. liver cirrhosis \> child a (patients with child b/c cirrhosis are excluded from the trial) 16. chronic kidney disease with gfr \< 30 ml/min 17. concurrent or planned anticancer treatment during trial period 18. accommodation in an institution due to legal orders (§40(4) amg). 19. any psycho-social condition hampering compliance with the study protocol. 20. evidence of current drug or alcohol abuse. 21. use of other investigational treatment within 5 half-lives of enrollment is prohibited 22. previous use of convalescent plasma for covid-19 23. concomitant proven influenza a infection 24. patients with organ or bone marrow transplant in the three months prior to screening visit

age <18 years unable to give informed consent pregnant women or breast-feeding mothers previous transfusion reaction or other contraindication to a plasma transfusion known hypersensitivity to camostat mesylate and/or severe pancreatitis volume stress due to cp administration would be intolerable known iga deficiency life expectancy < 6 months duration sars-cov-2 typical symptoms > 3 days sars-cov-2 pcr detection older than 3 days sars-cov-2 associated clinical condition >= who stage 3 (patients hospitalized for other reasons than covid-19 may be included if they fulfill all inclusion and none of the exclusion criteria). previously or currently hospitalized due to sars-cov-2 previous antiviral therapy for sars-cov-2 alanine aminotransferase (alt) or aspartate transferase (ast) > 5 times upper limit of normal (uln) at screening liver cirrhosis > child a (patients with child b/c cirrhosis are excluded from the trial) chronic kidney disease with gfr < 30 ml/min concurrent or planned anticancer treatment during trial period accommodation in an institution due to legal orders (§40(4) amg). any psycho-social condition hampering compliance with the study protocol. evidence of current drug or alcohol abuse. use of other investigational treatment within 5 half-lives of enrollment is prohibited previous use of convalescent plasma for covid-19 concomitant proven influenza a infection patients with organ or bone marrow transplant in the three months prior to screening visit

age <18 years unable to give informed consent pregnant women or breast-feeding mothers previous transfusion reaction or other contraindication to a plasma transfusion known hypersensitivity to camostat mesylate and/or severe pancreatitis volume stress due to cp administration would be intolerable known iga deficiency life expectancy < 6 months duration sars-cov-2 typical symptoms > 3 days sars-cov-2 pcr detection older than 3 days sars-cov-2 associated clinical condition >= who stage 3 (patients hospitalized for other reasons than covid-19 may be included if they fulfill all inclusion and none of the exclusion criteria). previously or currently hospitalized due to sars-cov-2 previous antiviral therapy for sars-cov-2 alanine aminotransferase (alt) or aspartate transferase (ast) > 5 times upper limit of normal (uln) at screening liver cirrhosis > child a (patients with child b/c cirrhosis are excluded from the trial) chronic kidney disease with gfr < 30 ml/min concurrent or planned anticancer treatment during trial period accommodation in an institution due to legal orders (§40(4) amg). any psycho-social condition hampering compliance with the study protocol. evidence of current drug or alcohol abuse. use of other investigational treatment within 5 half-lives of enrollment is prohibited previous use of convalescent plasma for covid-19 concomitant proven influenza a infection patients with organ or bone marrow transplant in the three months prior to screening visit

1. age <18 years 2. unable to give informed consent 3. pregnant women or breast-feeding mothers 4. previous transfusion reaction or other contraindication to a plasma transfusion 5. known hypersensitivity to camostat mesylate and/or severe pancreatitis 6. volume stress due to cp administration would be intolerable 7. known iga deficiency 8. life expectancy < 6 months 9. duration sars-cov-2 typical symptoms > 3 days 10. sars-cov-2 pcr detection older than 3 days 11. sars-cov-2 associated clinical condition >= who stage 3 (patients hospitalized for other reasons than covid-19 may be included if they fulfill all inclusion and none of the exclusion criteria). 12. previously or currently hospitalized due to sars-cov-2 13. previous antiviral therapy for sars-cov-2 14. alanine aminotransferase (alt) or aspartate transferase (ast) > 5 times upper limit of normal (uln) at screening 15. liver cirrhosis > child a (patients with child b/c cirrhosis are excluded from the trial) 16. chronic kidney disease with gfr < 30 ml/min 17. concurrent or planned anticancer treatment during trial period 18. accommodation in an institution due to legal orders (§40(4) amg). 19. any psycho-social condition hampering compliance with the study protocol. 20. evidence of current drug or alcohol abuse. 21. use of other investigational treatment within 5 half-lives of enrollment is prohibited 22. previous use of convalescent plasma for covid-19 23. concomitant proven influenza a infection 24. patients with organ or bone marrow transplant in the three months prior to screening visit

1. age <18 years 2. unable to give informed consent 3. pregnant women or breast-feeding mothers 4. previous transfusion reaction or other contraindication to a plasma transfusion 5. known hypersensitivity to camostat mesylate and/or severe pancreatitis 6. volume stress due to cp administration would be intolerable 7. known iga deficiency 8. life expectancy < 6 months 9. duration sars-cov-2 typical symptoms > 3 days 10. sars-cov-2 pcr detection older than 3 days 11. sars-cov-2 associated clinical condition >= who stage 3 (patients hospitalized for other reasons than covid-19 may be included if they fulfill all inclusion and none of the exclusion criteria). 12. previously or currently hospitalized due to sars-cov-2 13. previous antiviral therapy for sars-cov-2 14. alanine aminotransferase (alt) or aspartate transferase (ast) > 5 times upper limit of normal (uln) at screening 15. liver cirrhosis > child a (patients with child b/c cirrhosis are excluded from the trial) 16. chronic kidney disease with gfr < 30 ml/min 17. concurrent or planned anticancer treatment during trial period 18. accommodation in an institution due to legal orders (§40(4) amg). 19. any psycho-social condition hampering compliance with the study protocol. 20. evidence of current drug or alcohol abuse. 21. use of other investigational treatment within 5 half-lives of enrollment is prohibited 22. previous use of convalescent plasma for covid-19 23. concomitant proven influenza a infection 24. patients with organ or bone marrow transplant in the three months prior to screening visit